Moreover, liver-specific AMPK knockout mice exhibited more severe pathology characteristic of NAFLD, including enhanced hepatic steatosis, oxidative stress, liver function damage and inflammatory responses, which indicated that AMPK is a potential target for the treatment and prevention of NAFLD (Strzyz, 2020). Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.